The present study proposal could be able to provide an answer to the following questions:1) what is the effect of the oral administration of levodopa on the synaptic dopamine concentration in end-stage Parkinson*s disease?2) how does microlesioning…
ID
Source
Brief title
Condition
- Movement disorders (incl parkinsonism)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The levodopa-induced change in synaptic dopamine concentration after versus
before DBS.
Secondary outcome
The baseline dopamine receptor binding before and after DBS.
Background summary
The (sub)acute effects on the dopamine household of deep brain stimulation as a
treatment modality in moderate to advanced Parkinson*s disease is still
incompletely understood.
Study objective
The present study proposal could be able to provide an answer to the following
questions:
1) what is the effect of the oral administration of levodopa on the synaptic
dopamine concentration in end-stage Parkinson*s disease?
2) how does microlesioning the STN/GPi influence the baseline dopamine receptor
binding?
3) how does microlesioning the STN/GPi influence the levodopa-induced change in
synaptic dopamine concentration?
4) what is the relationship between the motor behaviour in general and the
occurrence of wearing-off fluctuations and dyskinesias in particular after the
STN procedure and the measured levodopa-induced changes in synaptic dopamine
concentration levels?
Study design
A longitudinal study with two imaging assessment points namely before and after
scheduled deep brain stimulation.
Study burden and risks
The burden of the present study lies in the amount of time spent during the
imaging session (two times 3 hours), the clinical assessments before and after
deep brain stimulation (dyskinesia scaling), the associated radiation risks
related to positron emission tomography scanning (6 mSv) and the fact of being
sobre both concerning food and dopaminergic medication up to 12 hours before
scanning.
There is no direct benefit related to the study apart from an even more
complete assessment of the patient.
Hanzeplein 1
9713 GZ Groningen
Nederland
Hanzeplein 1
9713 GZ Groningen
Nederland
Listed location countries
Age
Inclusion criteria
Patients with end-stage Parkinson*s disease, being scheduled for deep brain stimulation.
Exclusion criteria
None.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL21380.042.08 |